Wasutorn Yangwanitset
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wasutorn Yangwanitset has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Melanie Jane Hezzell
Bristol Veterinary School University of Bristol Bristol UK
2 shared publications - A. Jakubczak
University of Liverpool, School of Veterinary Science, Institute of Infection, Veterinary and Ecological Sciences, Leahurst Campus, Neston, CH64 7TE UK; Cheshire Cardiology, The Old School House, Chester Rd, Northwich CW8 1LE UK
1 shared publication - David A. Singleton
IVC Evidensia UK, The Chocolate Factory, Keynsham, Bristol, BS31 2AU UK
1 shared publication - Elizabeth. F. Bode
Chester Gates Veterinary Specialists, Units E & F, Telford Court, Gates Lane, Chester, Cheshire, CH1 6LT UK
1 shared publication - Emily Dutton
Cheshire Cardiology, The Old School House, Chester Rd, Northwich CW8 1LE UK
1 shared publication - Gavin McAulay
Brighton Veterinary Referrals, The Veterinary Hospital, The Deneway, London Road, East Sussex, BN1 8QR, UK; Brighton Veterinary Cardiology, Brighton, UK; North Downs Specialist Referrals, The Friesian Buildings 3 & 4, The Brewer street, Dairy Business Park, Brewer Street, Bletchingley, RH1 4QP, UK
1 shared publication
Latest Publications
- Open Access
- 14 August 2026
- Published by Wiley in Veterinary Medicine and Science
- Vol. 12 (5) , e71159
Adjunctive Therapy With a Perna canaliculus and Euphausia superba Extract (EAB‐277 TM ) for Clinical Signs of Tracheal Collapse in Dogs: A Prospective, Randomized and Placebo‐Controlled Exploratory Trial
Background: Tracheal collapse is a common canine respiratory disease characterized by dorsoventral cartilage flattening, airway lumen narrowing and subsequent mucosal inflammation. Objectives: To investigate the efficacy of EAB‐277, a marine lipid extract combining Perna canaliculus (30 mg) and Euphausia superba (20 mg) as an adjunctive therapy in the management of tracheal collapse in dogs. Methods: Forty‐one dogs with confirmed tracheal collapse were randomly assigned to receive standard conventional medications plus either EAB‐277 ( n = 21) or a placebo ( n = 20). The EAB‐277 treatment protocol included a loading dose for the initial 14 days. Clinical signs and quality of life were assessed together with fluoroscopy, radiography, haematology and serum biochemistry on Days 0, 14, 28 and 56. Results: Dogs receiving EAB‐277 showed a significant improvement in exercise tolerance by Day 14. Concurrently, fluoroscopic analysis demonstrated significant reductions in the percentage change in tracheal luminal diameter across the cervical, thoracic inlet and intrathoracic regions by Day 14. Both groups showed significant improvements in cough scores throughout the study, with no statistical difference between the groups. Conclusions: Although conventional medical therapy effectively manages the clinical signs of tracheal collapse, particularly cough, this study demonstrates that EAB‐277 provides additional benefits by significantly improving exercise tolerance and reducing dynamic tracheal collapse at the cervical, thoracic inlet and intra‐thoracic regions, which might have the potential to enhance airway health.
- 14 August 2026
- Published by Wiley in Veterinary Medicine and Science
- Vol. 12 (5) , e71159
Open AccessAdjunctive Therapy With a Perna canaliculus and Euphausia superba Extract (EAB‐277 TM ) for Clinical Signs of Tracheal Collapse in Dogs: A Prospective, Randomized and Placebo‐Controlled Exploratory Trial
Background: Tracheal collapse is a common canine respiratory disease characterized by dorsoventral cartilage flattening, airway lumen narrowing and subsequent mucosal inflammation. Objectives: To investigate the efficacy of EAB‐277, a marine lipid extract combining Perna canaliculus (30 mg) and Euphausia superba (20 mg) as an adjunctive therapy in the management of tracheal collapse in dogs. Methods: Forty‐one dogs with confirmed tracheal collapse were randomly assigned to receive standard conventional medications plus either EAB‐277 ( n = 21) or a placebo ( n = 20). The EAB‐277 treatment protocol included a loading dose for the initial 14 days. Clinical signs and quality of life were assessed together with fluoroscopy, radiography, haematology and serum biochemistry on Days 0, 14, 28 and 56. Results: Dogs receiving EAB‐277 showed a significant improvement in exercise tolerance by Day 14. Concurrently, fluoroscopic analysis demonstrated significant reductions in the percentage change in tracheal luminal diameter across the cervical, thoracic inlet and intrathoracic regions by Day 14. Both groups showed significant improvements in cough scores throughout the study, with no statistical difference between the groups. Conclusions: Although conventional medical therapy effectively manages the clinical signs of tracheal collapse, particularly cough, this study demonstrates that EAB‐277 provides additional benefits by significantly improving exercise tolerance and reducing dynamic tracheal collapse at the cervical, thoracic inlet and intra‐thoracic regions, which might have the potential to enhance airway health.